Table 2.
Comparison by univariate and multivariate analysis of deceased and surviving patients
| Alive (N = 384) | Deceased (N = 53) | p-value | Multivariate analysis OR (95%IC) p-value | |
|---|---|---|---|---|
| Characteristics | ||||
| Age, years, median (Q1;Q3) | 64 (55;72) | 71 (66;77) | < 0.001 | 1.09 (1.04;1.15), p = 0.001 |
| Smoking, n (%) | 84 (22%) | 16 (31%) | NS | - |
| Coronary artery disease, n (%) | 36 (9%) | 15 (29%) | 0.001 | - |
| Hypertension, n (%) | 158 (41%) | 31 (60%) | 0.013 | - |
| Chronic kidney disease, n (%) | 26 (7%) | 13 (25%) | < 0.001 | - |
| Diabete mellitus, n (%) | 38 (10%) | 10 (19%) | 0.048 | - |
| Chronic pulmonary disease, n (%) | 76 (20%) | 18 (35%) | 0.0165 | - |
| Charlson score, median (Q1;Q3) | 1 (0;2) | 2 (1;5) | < 0.001 | 1.23 (1.02;1.48), p = 0.028 |
| ICU admission | ||||
| SAPS II, median (Q1;Q3) | 31 (21;42) | 49 (40;63) | < 0.001 | - |
| SOFA score, median (Q1;Q3) | 3 (2;7) | 8 (6;10) | < 0.001 | 1.40 (1.19;1.66), p < 0.001 |
| PaO2/FiO2 ratio, median (Q1;Q3) | 150 (110;188) | 130 (90;168) | 0,039 | - |
| CRP, mg/L, median (Q1;Q3) | 140 (81.2;212.5) | 173.4 (121.5;258.4) | 0.0337 | - |
| Lactates, mmol/L, median (Q1;Q3) | 1.2 (1;1.6) | 1.6 (1.2;2) | < 0.001 | 1.61 (1.15;2.40), p = 0.011 |
| D-dimer, ng/mL, median (Q1;Q3) | 943 (573;1739) | 1447 (811;4000) | 0.0066 | - |
| Lymphocytes 109/L, median (Q1;Q3) | 0.71 (0.52;0.93) | 0.585 (0.4;0.76) | 0.0273 | - |
| ICU stay | ||||
| MV, n (%) | 236 (61%) | 46 (87%) | < 0.001 | - |
| Delay admission-MV, days, median (Q1;Q3) | 0;1 (0) | 0 (0;1) | NS | - |
| Prone position, n (%) | 127 (33%) | 35 (66%) | < 0.001 | 4.25 (1.62;12.65),.p = 0.005 |
| Duration of MV, days, median (Q1;Q3) | 9 (5;19) | 11 (5;26) | NS | - |
| Vasopressorsa, n (%) | 29 (8%) | 19 (36%) | < 0.001 | - |
| AKI, n (%) | 106 (28%) | 29 (56%) | < 0.001 | - |
| Dexamethasone, n (%) | 322 (84%) | 35 (66%) | 0.0022 | - |
| RRT, n (%) | 29 (8%) | 25 (47%) | < 0.001 | - |
| ICU LOS, days, median (Q1;Q3) | 8 (4;14.3) | 9 (5;20) | NS | - |
SAPSII simplified acute physiologic score, SOFA sequential organ failure assessment, MV mechanical ventilation, AKI acute kidney injury, VAP ventilated associated pneumonia, CAPA Covid19 associated pulmonary aspergillosis, RRT renal replacement therapy, LOS length of stay, ICU intensive care unit
anorepinephrine > 0.3µg/kg/min